Stockscreener 앱 받기
47.48
4.89%
-2.44
시간 외 거래:
48.12
0.64
+1.35%
전일 마감가:
$49.92
열려 있는:
$50.1
하루 거래량:
539.61K
Relative Volume:
0.69
시가총액:
$2.05B
수익:
$4.85M
순이익/손실:
$-114.75M
주가수익비율:
-14.61
EPS:
-3.25
순현금흐름:
$-100.36M
1주 성능:
+1.93%
1개월 성능:
+21.37%
6개월 성능:
+138.59%
1년 성능:
+106.35%
1일 변동 폭
$45.64
$50.10
1주일 범위
$45.64
$53.33
52주 변동 폭
$13.37
$57.50
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
명칭
Dianthus Therapeutics Inc
전화
929-999-4055
주소
7 TIMES SQUARE, NEW YORK
Compare DNTH vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
47.48 | 2.16B | 4.85M | -114.75M | -100.36M | -3.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-14 | 개시 | Truist | Buy |
| 2025-07-02 | 개시 | William Blair | Outperform |
| 2024-12-20 | 개시 | TD Cowen | Buy |
| 2024-10-03 | 개시 | Oppenheimer | Outperform |
| 2024-07-26 | 개시 | Robert W. Baird | Outperform |
| 2024-06-27 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-05-16 | 개시 | H.C. Wainwright | Buy |
| 2024-02-15 | 개시 | Stifel | Buy |
| 2023-12-26 | 개시 | Jefferies | Buy |
| 2023-11-22 | 개시 | Wedbush | Outperform |
| 2023-10-30 | 개시 | Guggenheim | Buy |
| 2023-09-28 | 개시 | Raymond James | Outperform |
| 2022-08-25 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-01-06 | 업그레이드 | Goldman | Neutral → Buy |
| 2021-08-20 | 재개 | Goldman | Neutral |
| 2021-08-03 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-07-22 | 재확인 | B. Riley Securities | Buy |
| 2021-06-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-05-18 | 개시 | B. Riley Securities | Buy |
| 2021-01-07 | 개시 | Mizuho | Buy |
| 2020-06-08 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-03-25 | 다운그레이드 | Goldman | Buy → Neutral |
| 2019-03-15 | 개시 | Raymond James | Outperform |
모두보기
Dianthus Therapeutics Inc 주식(DNTH)의 최신 뉴스
DNTH: Key 2026 clinical milestones and strong commercial outlook drive optimism for pipeline success - TradingView
DNTH: Pivotal trial readouts and strong financials position the pipeline for major commercial impact - TradingView
What 4 Analyst Ratings Have To Say About Dianthus Therapeutics - Benzinga
Wedbush Boosts Dianthus Therapeutics (NASDAQ:DNTH) Price Target to $55.00 - MarketBeat
Candriam S.C.A. Purchases 60,852 Shares of Dianthus Therapeutics, Inc. $DNTH - MarketBeat
How Investors Are Reacting To Dianthus Therapeutics (DNTH) US$600 Million Universal Shelf Registration - simplywall.st
Assessing Dianthus Therapeutics (DNTH) Valuation After New US$600m Shelf Registration Filing - Sahm
Dianthus Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - 富途牛牛
Dianthus Therapeutics (DNTH) Price Target Increased by 10.51% to 75.99 - Nasdaq
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Short Interest Update - MarketBeat
Jefferies Financial Group Issues Positive Forecast for Dianthus Therapeutics (NASDAQ:DNTH) Stock Price - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Given New $81.00 Price Target at Jefferies Financial Group - MarketBeat
Biotech Stocks To Follow Today – January 30th - Defense World
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Biotech Stocks To Follow TodayJanuary 30th - MarketBeat
Dianthus Therapeutics stock hits 52-week high at 54.05 USD By Investing.com - Investing.com India
Dianthus Therapeutics, Inc. (DNTH) Stock Analysis: A Biotech Gem with 21.98% Upside Potential - DirectorsTalk Interviews
Dianthus Therapeutics (NASDAQ:DNTH) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Hits New 52-Week HighShould You Buy? - MarketBeat
Dianthus Therapeutics stock hits 52-week high at 54.05 USD - Investing.com
Oppenheimer Boosts Price Target on Dianthus Therapeutics to $125 From $62, Keeps Outperform Rating - marketscreener.com
Oppenheimer raises Dianthus Therapeutics stock price target to $125 from $62 - Investing.com Canada
Dianthus Therapeutics may issue up to $600 million in securities - marketscreener.com
Dianthus Therapeutics May Issue Up To $600 Million In Securities - TradingView
Dianthus Therapeutics (DNTH) Is Up 18.7% After Claseprubart Trial Progress Reshapes Its Autoimmune Focus - Sahm
Dianthus Therapeutics, Inc. (DNTH) Stock Analysis: Exploring a Potential 23% Upside in the Biotech Sector - DirectorsTalk Interviews
Dianthus Therapeutics, Inc. (DNTH) Moves 9.9% Higher: Will This Strength Last? - Nasdaq
Dianthus Therapeutics (NASDAQ:DNTH) Trading Up 10.3%What's Next? - MarketBeat
Dianthus Therapeutics stock hits 52-week high at 46.6 USD By Investing.com - Investing.com India
Dianthus Therapeutics (NASDAQ:DNTH) Sets New 12-Month HighShould You Buy? - MarketBeat
Dianthus Therapeutics stock hits 52-week high at 46.6 USD - Investing.com
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Short Interest Up 47.4% in December - MarketBeat
First Week of March 20th Options Trading For Dianthus Therapeutics (DNTH) - Nasdaq
Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 6.1%Should You Sell? - MarketBeat
Published on: 2026-01-15 20:27:08 - baoquankhu1.vn
Generalized Myasthenia Gravis Market Outlook Shows Strong Momentum During the Forecast Period (2025–2034) Driven by Novel Immunotherapies | DelveInsight - GlobeNewswire Inc.
Is Dianthus Therapeutics Inc. currently under institutional pressureJuly 2025 Setups & Growth Oriented Trading Recommendations - bollywoodhelpline.com
Dianthus Therapeutics (NASDAQ:DNTH) Sets New 1-Year HighShould You Buy? - MarketBeat
Dianthus Therapeutics stock hits 52-week high at $45.56 By Investing.com - Investing.com Nigeria
Trading Recap: How Dianthus Therapeutics Inc stock reacts to bond yieldsWeekly Stock Summary & Free Safe Capital Growth Stock Tips - Bộ Nội Vụ
Dianthus Therapeutics (NASDAQ:DNTH) Trading Up 12%Here's What Happened - MarketBeat
Breakout Zone: Whats the RSI of Dianthus Therapeutics Inc stock2025 Risk Factors & High Accuracy Swing Trade Signals - baoquankhu1.vn
Dianthus Therapeutics stock hits 52-week high at $45.56 - Investing.com
Fed Watch: How Dianthus Therapeutics Inc stock responds to policy changesJuly 2025 Snapshot & Weekly High Momentum Picks - Bộ Nội Vụ
Assessing Dianthus Therapeutics (DNTH) Valuation As Price To Book Sits Near 3x And Shares Show Mixed Returns - Yahoo Finance
Truist Financial Sticks to Its Buy Rating for Dianthus Therapeutics (DNTH) - The Globe and Mail
Will Dianthus Therapeutics Inc. stock gain from lower inflation2025 Institutional Moves & Low Risk Profit Maximizing Plans - Улправда
Can Dianthus Therapeutics Inc. stock hit record highs againJuly 2025 Sentiment & Risk Managed Investment Entry Signals - Улправда
Why Dianthus Therapeutics Inc. stock could outperform in 2025Portfolio Update Summary & Real-Time Volume Triggers - Улправда
DNTH: Analyst Raises Price Target to $63, Maintains Buy Rating | - GuruFocus
Truist Financial Raises Dianthus Therapeutics (NASDAQ:DNTH) Price Target to $63.00 - MarketBeat
Dianthus Therapeutics Inc (DNTH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Dianthus Therapeutics Inc 주식 (DNTH) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Savitz Ryan | CFO & CBO |
Dec 04 '25 |
Sale |
45.18 |
20,000 |
903,600 |
0 |
1.24%
0.19%
자본화:
|
볼륨(24시간):